Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis
- PMID: 11810178
- DOI: 10.1007/s004010100444
Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis
Abstract
We characterized the early effects of anti-very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) antibody therapy on T cell infiltration and apoptosis in adoptive transfer experimental autoimmune neuritis of female Lewis rats. At the peak of disease, animals were treated with anti-VCAM-1 monoclonal antibody (mAb), anti-VLA-4 mAb, or the respective isotype mAb controls 18, 12, or 6 h before perfusion. Anti-VCAM-1 led to a rapid, significant increase of apoptotic T cells in the sciatic nerve with a maximum after 6 h, preceding the significant decrease of T cell infiltration seen after 18 h. This was accompanied by a significant reduction in mRNA levels for IFN-gamma and inducible nitric oxide synthase. The results for anti-VLA-4 treatment showed a similar trend. The early increase of T cell apoptosis following disruption of VLA-4/VCAM-1 interaction may reflect a novel signaling component of proapoptotic pathways.
Similar articles
-
The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat.Brain. 1998 Jul;121 ( Pt 7):1257-66. doi: 10.1093/brain/121.7.1257. Brain. 1998. PMID: 9679778
-
Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.Eur J Pharmacol. 2007 Mar 22;559(2-3):202-9. doi: 10.1016/j.ejphar.2006.11.065. Epub 2006 Dec 12. Eur J Pharmacol. 2007. PMID: 17234179
-
Endothelial expression of VCAM-1 in experimental crescentic nephritis and effect of antibodies to very late antigen-4 or VCAM-1 on glomerular injury.J Immunol. 1999 May 1;162(9):5519-27. J Immunol. 1999. PMID: 10228033
-
Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale.Neurology. 2005 Apr 26;64(8):1336-42. doi: 10.1212/01.WNL.0000158329.30470.D0. Neurology. 2005. PMID: 15851719 Review.
-
VLA-4 and its ligands: relevance to kidney diseases.Springer Semin Immunopathol. 1995;16(4):417-25. doi: 10.1007/BF00196097. Springer Semin Immunopathol. 1995. PMID: 7570292 Review.
Cited by
-
Infectious Complications of Novel Multiple Sclerosis Therapies.Curr Infect Dis Rep. 2017 Feb;19(2):7. doi: 10.1007/s11908-017-0562-0. Curr Infect Dis Rep. 2017. PMID: 28233190 Review.
-
Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders.PLoS One. 2011 Apr 20;6(4):e18506. doi: 10.1371/journal.pone.0018506. PLoS One. 2011. PMID: 21533133 Free PMC article. Clinical Trial.
-
Disease-modifying therapies and infectious risks in multiple sclerosis.Nat Rev Neurol. 2016 Apr;12(4):217-33. doi: 10.1038/nrneurol.2016.21. Epub 2016 Mar 4. Nat Rev Neurol. 2016. PMID: 26943779 Review.
-
Integrin-directed antibody-based immunotherapy: focus on VLA-4.Immunother Adv. 2021 Feb 9;1(1):ltab002. doi: 10.1093/immadv/ltab002. eCollection 2021 Jan. Immunother Adv. 2021. PMID: 35919739 Free PMC article. Review.
-
The Molecular Mechanisms of Vitamin A Deficiency in Multiple Sclerosis.J Mol Neurosci. 2016 Sep;60(1):82-90. doi: 10.1007/s12031-016-0781-0. Epub 2016 Jun 29. J Mol Neurosci. 2016. PMID: 27356515 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous